

miR-561 inhibits gastric cancer via c-Myc

Table S1. Clinicopathologic characteristics of patients with GC

Parameter	Total samples	Percentage	miR-561 expression		P
			Low (n%)	High (n%)	
Age (years)					0.61
≥60	32	64%	28	4	
<60	18	36%	16	2	
Gender					0.73
Male	34	68%	30	4	
Female	16	32%	14	2	
Clinical TNM stage					
I	10	20%	6	4	
II	18	36%	16	2	
III	15	30%	15	0	
IV	7	14%	7	0	
Location					0.66
Proximal	22	44%	20	2	
Body	28	56%	24	4	
Metastasis					0.001
Present	7	14%	7	0	
Absent	43	86%	37	6	
Histological					
Diffuse	23	46%	21	2	0.69
Intestinal	27	54%	23	4	

Table S2. Primer sequence

Name	Sequence (5'-3')
miRNA reverse transcription prime	
miRNA-561	GTATCCAGGTCTGCAGGGTCCGAGGTATACTGGATCGCTACGACTCACAT
U6 snRNA	AAAATATGGAACGCTTCACGAATTG
Real-time PCR primer sequence	
miRNA-561	CAAAGUUUAAGAUCUUUGAAGU TCAACTGGTGTCTGGAGTCGGC
U6 snRNA	CTCGCTTCGGCAGCACATATACT ACGCTTCACGAATTTGCGTGTC
GAPDH	AATGGGCAGCCGTTAGGAAA TGAAGGGGTCATTGATGGCA
c-Myc	TGCTAAGAAGATTGGTCTGTA GCGAAGGGCTGAGACATTAC